Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

Trial Identifier: 217741
Sponsor: GlaxoSmithKline
Collaborator:
CureVac
Start Date: March 2022
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Colorado Aurora, Colorado, United States, 80012-4520
United States, Florida Hallandale Beach, Florida, United States, 33009
United States, Florida Lakeland, Florida, United States, 33803
United States, Florida Lakeland, Florida, United States, 33803-5918
United States, Florida Miami, Florida, United States, 33173
United States, Florida MIami, Florida, United States, 33173
United States, Florida Palm Springs, Florida, United States, 33406
United States, Illinois Oak Brook, Illinois, United States, 60523
United States, Ohio Cleveland, Ohio, United States, 44122
United States, Oklahoma Norman, Oklahoma, United States, 73072
United States, Oklahoma Oklahoma City, Oklahoma, United States, 73112
United States, Texas Cedar Park, Texas, United States, 78613
United States, Texas Dallas, Texas, United States, 75203-1259
United States, Texas Dallas, Texas, United States, 75234
United States, Texas Plano, Texas, United States, 75093
United States, Texas Tomball, Texas, United States, 77375
United States, Utah West Jordan, Utah, United States, 84088